SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of better treatments for patients worldwide, entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.

旧金山，2024年5月8日（环球通讯社）--Siren Biotechnology是癌症通用AAV免疫基因治疗的先驱，Catalent Inc.是为全球患者开发和提供更好治疗的领导者，他们建立了战略合作伙伴关系，以支持Siren Biotechnology AAV免疫基因治疗的开发和制造。

Under the partnership, Catalent will provide process development and cGMP manufacturing of Siren Biotechnology’s adeno-associated viral (AAV) vector-based therapeutic candidates for use in clinical trials. Catalent will further support process optimization at its process and clinical development center in Baltimore, MD.

根据该合作关系，Catalent将提供Siren Biotechnology基于腺相关病毒（AAV）载体的治疗候选物的工艺开发和cGMP制造，用于临床试验。Catalent将在马里兰州巴尔的摩的过程和临床开发中心进一步支持过程优化。

“We look forward to working with Catalent, a leading CDMO with premier capabilities in AAV vector development and manufacturing, on the development of our AAV Immuno-Gene Therapies,” said Dr. Nicole Paulk, CEO, Founder, and President of Siren Biotechnology. “This partnership demonstrates our commitment to a robust manufacturing process that will move our therapeutic programs into the clinic as quickly as possible.

Siren Biotechnology首席执行官、创始人兼总裁Nicole Paulk博士表示：“我们期待着与Catalent合作，Catalent是一家领先的CDMO，在AAV载体开发和制造方面具有卓越的能力，开发我们的AAV免疫基因疗法。”。“这种合作关系表明了我们对强大制造过程的承诺，这将使我们的治疗计划尽快进入临床。

Catalent is the only CDMO in the U.S. that has received FDA approval for AAV-based gene therapies to date, and this was a significant factor in our decision to partner with Catalent as we plan for future commercialization of our upcoming clinical drug products.” David McErlane, Group President of Biologics at Catalent stated, “Catalent is committed to partnering early in the development process with innovative companies like Siren.

迄今为止，Catalent是美国唯一获得FDA批准的基于AAV的基因疗法的CDMO，这是我们决定与Catalent合作的一个重要因素，因为我们计划未来将推出的临床药物产品商业化。”加泰罗尼特生物制剂集团总裁DavidMcErlange表示：“加泰罗尼特致力于在开发过程的早期与Siren等创新公司合作。

We are excited to work together to pioneer a pathway for the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to patients with cancer.” About Siren Biotechnology Headquartered in San Fr.

我们很高兴能够携手合作，开创一条安全、高质量AAV基因疗法的开发和商业制造之路，为癌症患者提供挽救生命的治疗。”关于Siren Biotechnology总部位于旧金山。